HOPO Therapeutics

📍 San Francisco Bay Area, United States🗓 Founded 2020👥 16 employees💰 Last funded May 2025
Biotechnology Research🌐 hopotx.com
Website LinkedIn
HOPO Therapeutics is a privately-held, clinical-stage pharmaceutical company developing treatments for heavy metal poisoning and pioneering novel methods for directed radioisotope delivery. Leveraging world-class expertise in the chemistry and biochemistry of heavy metals and technology licensed from Lawrence Berkeley National Laboratory, HOPO’s mission is to safeguard all people throughout the world from the harmful effects of heavy metal contamination while utilizing the power of metals in medicine to cure disease and improve lives.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in HOPO Therapeutics?
HOPO Therapeutics has 1 investors on record on gritt.io, 1 mid-stage.
When did HOPO Therapeutics last raise funding?
The most recent investment in HOPO Therapeutics recorded on gritt.io was in May 2025.
When was HOPO Therapeutics founded?
HOPO Therapeutics was founded in 2020.
What industry is HOPO Therapeutics in?
HOPO Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is HOPO Therapeutics based?
HOPO Therapeutics is headquartered in San Francisco Bay Area, United States.